secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-07-10T20:02:00+00:00
Accession:  0001213900-26-077127
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed amends merger with Mentari; files S-4; clarifies name change, redomestication, tax treatment
--------------------------------------------------------------------------------

- Amendment clarifies sequencing: InMed will change name to Mentari Therapeutics and redomesticate to Nevada before closing.
- Amendment introduces Company PIPE Amendment concept to facilitate additional pre-closing financing and clarifies impact on exchange ratio.
- Tax treatment clarified: First and Second Mergers intended to qualify as a reorganization under Section 368(a) of the IRC.
- Merger expected to close in Q4 2026, subject to shareholder approvals, S-4 effectiveness, and other conditions.
- InMed filed Form S-4 on July 2, 2026, containing preliminary proxy statement/prospectus and management information circular.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026077127/0001213900-26-077127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026077127/ea0297284-8k425_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-077127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer